Table 2.
The results of the meta-analysis and subgroup analysis.
| No. of studies | Pooled effect sizes (95% CI) | Heterogeneity | P of Egger’s for publication bias | |||
|---|---|---|---|---|---|---|
| I2 (%) | P | |||||
| Inflammation remission (%) | 15 | 68.2 (59.1, 78.8) | 89.3 | <0.001 | 0.014 | |
| Study location | ||||||
| Asia | 7 | 54.3 (39.7, 74.4) | 88.5 | <0.001 | ||
| Europe | 6 | 82.1 (72.6, 92.7) | 82.9 | <0.001 | ||
| Study design | ||||||
| Retrospective study | 11 | 71.3 (60.9, 83.5) | 90.2 | <0.001 | ||
| Prospective study | 3 | 58.3 (45.6, 74.6) | 59.2 | 0.129 | ||
| Follow up (months) | ||||||
| <24 | 8 | 75.4 (64.2, 88.4) | 83.1 | <0.001 | ||
| ≥24 | 6 | 58.7 (43.7, 78.8) | 93.5 | <0.001 | ||
| Anti TNF agents | ||||||
| IFX | 8 | 53.7 (43.1, 66.8) | 77.6 | <0.001 | ||
| ADA | 4 | 91.3 (86.4, 96.5) | 0.0 | 0.639 | ||
| IFX, ADA | 2 | 76.9 (59.8, 98.8) | 87.3 | <0.001 | ||
| Corticosteroid suspended | 5 | 38.4 (22.8, 64.6) | 85.9 | <0.001 | 0.116 | |
| Study location | ||||||
| Asia | 2 | 44.4 (16.1, 100.0) | 94.2 | <0.001 | ||
| Europe | 3 | 34.3 (17.8, 66.0) | 76.0 | <0.001 | ||
| Follow up (months) | ||||||
| <24 | 2 | 30.5 (7.9, 100.0) | 87.9 | <0.001 | ||
| ≥24 | 3 | 42.3 (21.8, 82.1) | 89.6 | <0.001 | ||
| Anti TNF agents | ||||||
| IFX | 2 | 44.4 (16.1, 100.0) | 94.2 | <0.001 | ||
| ADA | 2 | 30.5 (7.9, 100.0) | 87.9 | <0.001 | ||
| Corticosteroid tapered | 3 | 33.9 (16.4, 69.8) | 71.8 | 0.029 | 0.210 | |
| CMT decrease(μm) a | 5 | -112.7 (-152.6, -72.8) | 70.2 | 0.009 | 0.911 | |
| Follow up (months) | ||||||
| <24 | 2 | -107.8 (-187.7, -27.8) | 87.0 | <0.001 | ||
| ≥24 | 3 | -117.1 (-169.0, -65.2) | 61.5 | 0.021 | ||
| Anti TNF agents | ||||||
| IFX | 2 | -102.1 (-177.0, -27.2) | 76.8 | <0.001 | ||
| IFX, ADA | 3 | -121.1 (-170.7, -71.4) | 67.2 | 0.011 | ||
| VA improvement | 8 | 60.3 (47.2, 77.0) | 86.6 | <0.001 | 0.206 | |
| Study location | ||||||
| Asia | 5 | 44.1 (31.0, 62.7) | 72.6 | 0.054 | ||
| Europe | 2 | 86.8 (77.7, 96.9) | 0.0 | 0.391 | ||
| Study design | ||||||
| Retrospective study | 6 | 50.7 (35.4, 72.6) | 88.0 | <0.001 | ||
| Prospective study | 2 | 82.3 (72.9, 92.9) | 0.0 | 0.784 | ||
| Anti TNF agents | ||||||
| IFX | 6 | 52.5 (38.5, 71.4) | 87.6 | <0.001 | ||
| ADA | 2 | 86.5 (71.0, 100.0) | 22.2 | 0.186 | ||
| Follow up (months) | ||||||
| <24 | 4 | 76.2 (59.5, 97.7) | 63.8 | 0.015 | ||
| ≥24 | 4 | 49.3 (33.0, 73.6) | 90.9 | <0.001 | ||
ADA, adalimumab; IFX, infliximab; CS, corticosteroid; CMT, central macular thickness; VA, visual acuity.
a
Difference between before and after treatment.